Groupe Berkem Société anonyme (ALKEM.PA)
| Previous close | 2.1200 |
| Open | 2.1100 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 2.1100 - 2.3100 |
| 52-week range | 1.1800 - 6.1000 |
| Volume | |
| Avg. volume | 14,497 |
| Market cap | 40.915M |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | 115.50 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 04 July 2022 |
| 1y target est | N/A |
- Business Wire
Groupe Berkem Unveils BiombalanceTM and Pineol® Premium, two Active Ingredients From Its New Nutraceutical Range
BLANQUEFORT, France, May 13, 2024--Regulatory News: Groupe Berkem (Paris:ALKEM), a leading player in bio-based chemistry (ISIN code: FR00140069V2 – Ticker: ALKEM), unveils today Pineol® Premium and BiombalanceTM, from its new range of premium ingredients for the Nutraceutical market.
- Business Wire
Groupe Berkem: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
BLANQUEFORT, France, May 03, 2024--Regulatory News: Groupe Berkem (Paris:ALKEM):
- Business Wire
Groupe Berkem Announces Its Full-Year 2023 Financial Results and Its Revenue for the First Quarter of 2024
BLANQUEFORT, France, April 30, 2024--Regulatory News: Groupe Berkem, a leading player in bio-based chemistry (ISIN code: FR00140069V2 – Ticker: ALKEM), announces its full-year financial results for the year ended December 31, 2023, as approved by its Board of Directors on April 26, 2024. The audit procedures on the full-year accounts have been conducted and the auditors' report is being issued. The Company also reports on its 2024 first-quarter revenue.
